I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $357.9M
ActivBiotics raised $26.4M in a Series B round led by MDS Capital Corp.; other investors were BioVentures Investors, F. Hoffmann-La Roche Ltd., China Development Industrial Bank, New England Partners, HealthCare Ventures LLC and Delphi Ventures LP
Biolex raised $24M in a round led by Quaker BioVentures and Intersouth Partners; other investors were Johnson & Johnson Development Corp., Mitsui & Co. Venture Partners, The Dow Chemical Co., Dogwood Equity, Trelys Venture Partners, The Wakefield Group, Kitty Hawk Capital, Franklin Street Partners, Tall Oaks Capital and Academy Centennial Fund
Research Triangle Park, N.C.
BioStratum raised $9.5M in a bridge financing; investors were HealthCap, BankInvest, Liftaeknisjodurinn hf and Equity Resources Group Inc.
CancerVax raised $41M in a Series C round of financing from a group of undisclosed new and existing investors
Chlorogen secured an undisclosed amount of venture funding from investors Burrill & Co., Redmont Venture Partners, Prolog Ventures and Harris & Harris Group Inc.
Clearant raised $18M in a Series B financing round, mostly from new institutional investors
Coley Pharmaceutical Group Inc.
Coley raised $35M in a private financing; investors were Thomas, McNerney & Partners; Venrock Associates; Techno Venture Management; and Global Life Science Ventures
GeneXP Biosciences Inc.
GeneXP raised $2M in a financing from Ingalls & Snyder LLC
GTx raised $20M in a financing with investors J.R. Hyde III, Oracle Partners LP and Memphis Biomed Ventures I LP
Kemia raised a total of more than $19M in a Series A financing; investors were Alta Partners, Forward Ventures and Texas Pacific Group, as well as Novartis BioVentures
Metabolex raised $27M in a financing co-led by Bay City Capital, BTF and CDP Capital Technology; other investors were Charter Ventures Capital and KBC; CIBC World Markets Corp. acted as agent for the financing
Myogen raised $40M in a Series D financing with a group of institutional investors led by New Enterprise Associates; other investors were J.P. Morgan, InterWest Partners, Sequel Venture Partners Ltd., Perseus-Soros Biopharmaceutical Fund LP,CMEA Ventures and Pacific Rim Ventures
San Carlos, Calif.
NuGEN raised $7.5M after completing a Series C round of financing led by William Rutter, George Rathmann and James Wilson; other investors were Sutter Hill Ventures, Radius Venture Partners, The Band of Angels Fund and MedCapital Ventures
South San Francisco
Renovis raised $45M through a Series E round led by Easton Hunt Capital Partners; other investors were HealthCap, MDS Capital, Invus Group, CDIB BioScience Ventures, Alta Partners, Venrock Associates, Flagship Ventures, Skyline Ventures and HBM BioVentures, among others
Rinat Neuroscience Corp.
Palo Alto, Calif.
Rinat raised $40M in a Series B round led by MPM Capital; other investors were Schroder Life Sciences, Prospect Venture Partners, Technology Partners and Essex Woodlands Health Ventures
Targeted Molecules Corp. Partnership, Inglewood Ventures LP, Linkagene
Targeted Molecules raised $3.5M in a private round; investors were Neuro Discovery Ltd. LP and Trian Equities Ltd.
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $19.8M
Laboratory Corp. of America Holdings (NYSE:LH)
Exact Sciences achieved a $15M milestone due to the national commercial availability of PreGen-Plus, a DNA-based stool assay for the early detection of colorectal cancer (8/13)
Genome Therapeutics Corp. (GENE)
Amgen Inc. (AMGN)
Genome Therapeutics received a payment from Amgen for the completion of a milestone under their agreement to use genetic information to discover and commercialize therapeutics for bone diseases, including osteoporosis (8/11)
Targeted Genetics Corp. (TGEN)
Biogen Inc. (BGEN)
Targeted received $4.8M through Biogen's purchase of 2.5M common shares (8/18)
TransForm Pharmaceuticals Inc.*
F. Hoffmann-La Roche Ltd. (Switzerland)
TransForm said it would receive an undisclosed milestone payment after making the first crystalline form of a compound belonging to Roche (8/5)
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
* Denotes privately held company.
ND = Not disclosed.
NYSE = New York Stock Exchange.